Primary HPV Screening vs Cotesting for Cervical Cancer
JAMA · 05.12.2023 · 330 (21) · 2121
DOI: 10.1001/jama.2023.20370 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, erschienen am 05.12.2023. Verfasst von Annika Brakebill und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, Ann Arbor. Hauptthemen laut MEDLINE: Early Detection of Cancer, Mass Screening, Papillomavirus Infections, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University of Michigan Medical School, Ann Arbor.
- Departments of Obstetrics & Gynecology and Pathology, University of Michigan, Ann Arbor.
Zitieren
APA
Brakebill, A., Morgan, A., & Lieberman, R. W. (2023). Primary HPV Screening vs Cotesting for Cervical Cancer. JAMA, 330(21), 2121. https://doi.org/10.1001/jama.2023.20370
Vancouver
Brakebill A, Morgan A, Lieberman RW. Primary HPV Screening vs Cotesting for Cervical Cancer. JAMA. 2023;330(21):2121. doi:10.1001/jama.2023.20370
BibTeX
@article{Brakebill2023,
author = {Brakebill, Annika and Morgan, Anna and Lieberman, Richard W},
title = {Primary HPV Screening vs Cotesting for Cervical Cancer},
journal = {JAMA},
year = {2023},
volume = {330},
number = {21},
pages = {2121},
doi = {10.1001/jama.2023.20370}
}
EUVIMED